Accession 492
Title Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs
Summary This study focused on the identification of molecular mechanisms causing resistance against the anti-ERBB2-directed therapeutic antibodies trastuzumab and pertuzumab presently used to treat patients with ERBB2-amplified breast cancer. Drug impact was quantified in cell viability assays and on the proteomic level using reverse-phase protein arrays.
Journal Oncogenesis
Publish date July, 2012
Corresponding Author U Korf
Array Type Reverse phase protein array
Species Homo sapiens
Raw data link


Link to PubMed

PubMed ID:23552733